US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NewcelX Ltd.

7.29

-0.3300-4.33%

Post-market: 7.11-0.1800-2.47%16:36 EDT

Volume:1.21M

Turnover:7.23M

Market Cap:33.23M

PE:-0.28

High:7.64

Open:5.08

Low:4.20

Close:7.62

52wk High:47.40

52wk Low:4.20

Shares:4.56M

Float Shares:4.56M

Volume Ratio:0.10

T/O Rate:26.65%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-26.2880

EPS(LYR):-26.2880

ROE:--

ROA:--

PB:--

PE(LYR):-0.28

Loading ...

Overview Company News Filings

NLS Pharmaceutics AG trading halted, news pending

BRIEF-NLS Pharmaceutics Ltd. And Kadimastem Ltd. Announce Completion Of Merger

NLS Pharmaceutics and Kadimastem Complete Merger to Form NewcelX

Press Release: NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger

NLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger

NLS Pharmaceutics and Kadimastem Secure Continued BIRD Foundation Support Following Merger

NLS Pharmaceutics: Following Merger Between Co and Kadimastem,Combined Co Will Continue to Advance Itol-102 Program

THOMSON REUTERS

BRIEF-Nls Pharmaceutics Announces 1-for-10 Reverse Share Split And Name Change In Connection With Proposed Merger With Kadimastem

NLS Pharmaceutics - Reverse Split Effective in Switzerland on October 30, 2025

THOMSON REUTERS

NLS Pharmaceutics - Common Shares to Trade on Nasdaq as Ncel Under New Name Newcelx Ltd

THOMSON REUTERS

NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection With Proposed Merger With Kadimastem

THOMSON REUTERS

Press Release: NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

NLS Pharmaceutics and Kadimastem Set October 30 Closing for Merger and Nasdaq Listing as NewCelX

NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration Between Kadimastem and Targetgene to Advance Next-Generation Gene-Edited Cell Therapies

THOMSON REUTERS

Press Release: NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies

Press Release: NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NCEL/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NCEL","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","market":"US","secType":"STK","nameCN":"NewcelX Ltd.","latestPrice":7.29,"timestamp":1761940800000,"preClose":7.62,"halted":0,"volume":1214619,"hourTrading":{"tag":"盘后","latestPrice":7.11,"preClose":7.29,"latestTime":"16:36 EDT","volume":12420,"amount":89100.52606799999,"timestamp":1761942996372},"delay":0,"floatShares":4558400,"shares":4558400,"eps":-26.28804,"marketStatus":"Post-Mkt","change":-0.33,"latestTime":"10-31 16:37:04 EDT","open":5.08,"high":7.64,"low":4.2,"amount":7225062.2515134,"amplitude":0.451444,"askPrice":7.25,"askSize":10,"bidPrice":6.85,"bidSize":21,"shortable":0,"etf":0,"ttmEps":-26.28804,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1761955200000},"marketStatusCode":4,"adr":0,"listingDate":1611896400000,"exchange":"NASDAQ","adjPreClose":7.62,"preHourTrading":{"tag":"盘前","latestPrice":5.26,"preClose":7.62,"latestTime":"09:29 EDT","volume":179418,"amount":1052985.1519248,"timestamp":1761917396617},"postHourTrading":{"tag":"盘后","latestPrice":7.11,"preClose":7.29,"latestTime":"16:36 EDT","volume":12420,"amount":89100.52606799999,"timestamp":1761942996372},"volumeRatio":0.101637},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NCEL\",,,,,undefined,":{"symbol":"NCEL","floatShares":4558400,"roa":"--","roe":"--","lyrEps":-26.28804,"volumeRatio":0.101637,"shares":4558400,"dividePrice":0,"high":7.64,"amplitude":0.451444,"preClose":7.62,"low":4.2,"week52Low":4.2,"pbRate":"--","week52High":47.4,"institutionHeld":0,"latestPrice":7.29,"committee":0.354839,"eps":-26.28804,"divideRate":0,"volume":1214619,"delay":0,"ttmEps":-26.28804,"open":5.08,"prevYearClose":2.11,"prevWeekClose":1.3,"prevMonthClose":1.83,"prevQuarterClose":1.83,"fiveDayClose":1.3,"twentyDayClose":1.995,"sixtyDayClose":2.02},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NCEL\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-10-31","symbol":"NCEL","defaultRemindTime":1761917400000,"type":"split","dateTimestamp":1761883200000,"forFactor":10,"toFactor":1,"ratio":10},{"market":"US","date":"2025-05-16","symbol":"NCEL","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1747368000000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-09-27","symbol":"NCEL","defaultRemindTime":1727443800000,"type":"split","dateTimestamp":1727409600000,"forFactor":40,"toFactor":1,"ratio":40}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NCEL\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NCEL\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NCEL\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2579107926","title":"NLS Pharmaceutics AG trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2579107926","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579107926?lang=en_us&edition=fundamental","pubTime":"2025-10-31 07:50","pubTimestamp":1761868215,"startTime":"0","endTime":"0","summary":"19:50 EDT NLS Pharmaceutics (NLSP) AG trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving bre...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nls-pharmaceutics-ag-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nls-pharmaceutics-ag-trading-halted-news-pending-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AG","BK4007","NLSP","BK4210"],"gpt_icon":0},{"id":"2579108707","title":"BRIEF-NLS Pharmaceutics Ltd. And Kadimastem Ltd. Announce Completion Of Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2579108707","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579108707?lang=en_us&edition=fundamental","pubTime":"2025-10-31 05:12","pubTimestamp":1761858761,"startTime":"0","endTime":"0","summary":"BRIEF-NLS Pharmaceutics Ltd. And Kadimastem Ltd. Announce Completion Of MergerOct 30 (Reuters) - NLS Pharmaceutics AG NLSP.O:NLS PHARMACEUTICS LTD. AND KADIMASTEM LTD. ANNOUNCE COMPLETION OF MERGERSource text: ID:nPn1P34QdaFurther company coverage: NLSP.O ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUABWSBVV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NLSP","NLSPW","BK4007"],"gpt_icon":0},{"id":"2579108639","title":"NLS Pharmaceutics and Kadimastem Complete Merger to Form NewcelX","url":"https://stock-news.laohu8.com/highlight/detail?id=2579108639","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579108639?lang=en_us&edition=fundamental","pubTime":"2025-10-31 04:57","pubTimestamp":1761857856,"startTime":"0","endTime":"0","summary":"The latest update is out from NLS Pharmaceutics ( ($NLSP) ). On October 30, 2025, NLS Pharmaceutics Ltd. completed its merger with Kadimastem Ltd.,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nls-pharmaceutics-and-kadimastem-complete-merger-to-form-newcelx?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nls-pharmaceutics-and-kadimastem-complete-merger-to-form-newcelx?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NLSP","BK4007"],"gpt_icon":0},{"id":"2579172809","title":"Press Release: NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Completion of Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2579172809","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579172809?lang=en_us&edition=fundamental","pubTime":"2025-10-31 04:15","pubTimestamp":1761855300,"startTime":"0","endTime":"0","summary":"Combined Company Re-Named NewcelX Ltd., to Commence Trading on the Nasdaq Capital Market on October 31, 2025 under the Ticker Symbol \"NCEL\". ZURICH and NESS ZIONA, Israel , Oct. 30, 2025 /PRNewswire/ --. Ronen Twito, Executive Chairman and Chief Executive Officer of NewcelX said, \"With the launch of NewcelX, we have brought together exceptional science and a global leadership team with the potential to change lives. The completion of the merger and the commencement of trading on Nasdaq mark a significant milestone that reflects the trust and confidence of our shareholders and investors, and I am deeply grateful for their support as we take this next step forward together. We are now preparing to initiate our Phase 2a clinica","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NLSPW","SQQQ","MNQmain","USJW.SI","QID","BK4588","PSQ","NVIW.SI","BK4099","NLSP","TM","TSYW.SI","QLD","USAW.SI","BK4007",".IXIC","03160","NQmain","BK4585","BK4555","TQQQ","BK4604"],"gpt_icon":1},{"id":"2579908191","title":"NLS Pharmaceutics and Kadimastem Continue ITOL-102 Diabetes Program Post-Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2579908191","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579908191?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:57","pubTimestamp":1761739079,"startTime":"0","endTime":"0","summary":"NLS Pharmaceutics ( ($NLSP) ) has shared an update. On October 29, 2025, NLS Pharmaceutics Ltd. and Kadimastem Ltd. announced the continuation of t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nls-pharmaceutics-and-kadimastem-continue-itol-102-diabetes-program-post-merger?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nls-pharmaceutics-and-kadimastem-continue-itol-102-diabetes-program-post-merger?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ITOL","BK4212","NLSP","NCEL","BK4007","POST"],"gpt_icon":0},{"id":"2579977259","title":"NLS Pharmaceutics and Kadimastem Secure Continued BIRD Foundation Support Following Merger","url":"https://stock-news.laohu8.com/highlight/detail?id=2579977259","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579977259?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:31","pubTimestamp":1761737478,"startTime":"0","endTime":"0","summary":"NLS Pharmaceutics Ltd. and Kadimastem Ltd. have completed a merger, bringing together their expertise in biopharmaceuticals and cell therapy. Following the merger, the ITOL-102 cell therapy program for Type 1 Diabetes, originally supported by a grant from the Israel-U.S. Binational Industrial Research and Development  Foundation, will continue development under the combined company. The collaboration aims to leverage Kadimastem's advanced stem-cell platform to expand the new pipeline into regenerative and metabolic medicine, with ongoing support from the BIRD Foundation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Ga","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDLbsPGlM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NLSP","NCEL","BK4007"],"gpt_icon":0},{"id":"2579972079","title":"NLS Pharmaceutics: Following Merger Between Co and Kadimastem,Combined Co Will Continue to Advance Itol-102 Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2579972079","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579972079?lang=en_us&edition=fundamental","pubTime":"2025-10-29 19:21","pubTimestamp":1761736865,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nFWN3WA1EA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NCEL","BK4007","NLSP"],"gpt_icon":0},{"id":"2579622975","title":"BRIEF-Nls Pharmaceutics Announces 1-for-10 Reverse Share Split And Name Change In Connection With Proposed Merger With Kadimastem","url":"https://stock-news.laohu8.com/highlight/detail?id=2579622975","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579622975?lang=en_us&edition=fundamental","pubTime":"2025-10-29 18:06","pubTimestamp":1761732392,"startTime":"0","endTime":"0","summary":"BRIEF-Nls Pharmaceutics Announces 1-for-10 Reverse Share Split And Name Change In Connection With Proposed Merger With KadimastemOct 29 (Reuters) - NLS Pharmaceutics AG NLSP.O:NLS PHARMACEUTICS LTD. A","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUA98VMQY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NLSP","NCEL","BK4007","NLSPW"],"gpt_icon":0},{"id":"2579975820","title":"NLS Pharmaceutics - Reverse Split Effective in Switzerland on October 30, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2579975820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579975820?lang=en_us&edition=fundamental","pubTime":"2025-10-29 18:00","pubTimestamp":1761732000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUA98VMQY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NLSPW","NCEL","NLSP"],"gpt_icon":0},{"id":"2579975353","title":"NLS Pharmaceutics - Common Shares to Trade on Nasdaq as Ncel Under New Name Newcelx Ltd","url":"https://stock-news.laohu8.com/highlight/detail?id=2579975353","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579975353?lang=en_us&edition=fundamental","pubTime":"2025-10-29 18:00","pubTimestamp":1761732000,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUA98VMQY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NLSP","NCEL","BK4007","NLSPW"],"gpt_icon":0},{"id":"2579973452","title":"NLS Pharmaceutics Ltd. Announces 1-for-10 Reverse Share Split and Name Change in Connection With Proposed Merger With Kadimastem","url":"https://stock-news.laohu8.com/highlight/detail?id=2579973452","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579973452?lang=en_us&edition=fundamental","pubTime":"2025-10-29 18:00","pubTimestamp":1761732000,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nTUA98VMQY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NCEL","BK4007","NLSPW","NLSP"],"gpt_icon":0},{"id":"2579921920","title":"Press Release: NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2579921920","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579921920?lang=en_us&edition=fundamental","pubTime":"2025-10-29 15:53","pubTimestamp":1761724380,"startTime":"0","endTime":"0","summary":"ZURICH and NESS ZIONA, Israel, Oct. 29, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.    and Kadimastem Ltd.   today announced that, following the receipt of Nasdaq's approval for the listing of the Company's common shares and the trading of the Company on the Nasdaq Capital Market after completion of the merger between the Company, NLS Pharmaceutics  Ltd., and Kadimastem , for the combined company's shares, all material conditions precedent to the completion of the Merger have been fulfilled or waived by the parties. The closing of the Merger has been set for October 30, 2025 .The final exchange ratio is 7.06 NLS common shares for each Kadimastem ordinary share. Following the implementation of the reverse share split of NLS's common shares on a 1:10 basis, the final ratio will be 0.706 NLS common shares per Kadimastem ordinary share.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["USAW.SI","PSQ","QLD","SQQQ","TQQQ","NCEL","MNQmain","NQmain","NLSP","NVIW.SI",".IXIC","QID","TSYW.SI","USJW.SI","BK4007","NLSPW"],"gpt_icon":1},{"id":"2579992611","title":"NLS Pharmaceutics and Kadimastem Set October 30 Closing for Merger and Nasdaq Listing as NewCelX","url":"https://stock-news.laohu8.com/highlight/detail?id=2579992611","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579992611?lang=en_us&edition=fundamental","pubTime":"2025-10-29 04:38","pubTimestamp":1761683915,"startTime":"0","endTime":"0","summary":"NLS Pharmaceutics and Kadimastem have completed all material conditions required for their merger, with the closing set for October 30, 2025. Following the merger, the combined company will be named NewCelX Ltd. and will be listed on the Nasdaq Capital Market under the ticker symbol \"NCEL\" starting October 31, 2025. Kadimastem's shares will be delisted from the Tel Aviv Stock Exchange on the same day. The final exchange ratio is 0.706 NLS common shares per Kadimastem ordinary share, following a 1:10 reverse share split of NLS's common shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NLS Pharmaceutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDLqzjh4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NCEL","NLSP"],"gpt_icon":0},{"id":"2578610857","title":"NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration Between Kadimastem and Targetgene to Advance Next-Generation Gene-Edited Cell Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2578610857","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578610857?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:00","pubTimestamp":1761562830,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nTUA3S18G8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NLSPW","NCEL","BK4007","NLSP"],"gpt_icon":0},{"id":"2578610662","title":"Press Release: NLS Pharmaceutics and Kadimastem Announce Strategic Collaboration between Kadimastem and TargetGene to Advance Next-Generation Gene-Edited Cell Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2578610662","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578610662?lang=en_us&edition=fundamental","pubTime":"2025-10-27 19:00","pubTimestamp":1761562800,"startTime":"0","endTime":"0","summary":"The collaboration will progress under the combined company, NewCelX, upon completion of the anticipated merger. ZURICH and NESS ZIONA, Israel, Oct. 27, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.  , a Swiss clinical-stage biopharmaceutical company focused on central nervous system and neurodegenerative disorders and Kadimastem Ltd.  , a clinical-stage biotechnology company developing breakthrough cell therapy solutions for severe diseases such as ALS and diabetes, today announced the signing of a Memorandum of Understanding  between Kadimastem and TargetGene Biotechnologies Ltd. , a pioneer in precision gene-editing technologies.This collaboration brings together Kadimastem's proprietary cell therapy platforms -- including AstroRx for ALS and IsletRx for diabetes -- with TargetGene's next-generation, DNA-guided gene-editing platform, enabling highly specific, multiplexed genome modifications with minimal off-target activity. The collaboration is expected to continue under the combined ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4232","NCEL","BK4007","NLSP","BK4022","R"],"gpt_icon":0},{"id":"2577937767","title":"Press Release: NLS and Kadimastem Announce Receipt of Nasdaq Approval; Merger Expected to Close on October 30, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2577937767","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577937767?lang=en_us&edition=fundamental","pubTime":"2025-10-23 18:01","pubTimestamp":1761213660,"startTime":"0","endTime":"0","summary":"ZURICH, Oct. 23, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd.   , a Swiss clinical-stage biopharmaceutical company focused on central nervous system  disorders, and Kadimastem Ltd.  , an advanced clinical-stage cell therapy company developing treatments for neurodegenerative diseases and diabetes, today announced an update regarding the proposed merger .On October 21, 2025, NLS received an approval letter from the Nasdaq Listing Center for the listing of its common shares and the trading of the Company on the Nasdaq Capital Market after completion of the Merger, under NLS's new name, NewcelX Ltd., with its new trading symbol for its common shares, \"NCEL\".Accordingly, the closing of the Merger is expected to close on October 30, 2025 , with the transition to trading under the combined company's new name beginning October 31, 2025, subject to fulfillment of the remaining customary closing conditions.-- At the end of the trading day on the Tel Aviv Stock Exchange  on. October 30, 2025, all","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MNQmain","BIRD","QID","BK4022","BK4232","USJW.SI","NQmain","QLD","R",".IXIC","NVIW.SI","PSQ","TSYW.SI","SQQQ","NLSP","BK4007","NCEL","USAW.SI","TQQQ","BK4146"],"gpt_icon":1}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":16,"code":"91000000","status":"200"}]}}